There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY 26 Suspected Violations in Detailing Activities Reported in FY2021: MHLW
August 12, 2022
-
BUSINESS Sumitomo Pharma to Rev Up R&D for Regenerative Medicine, CNS towards Later 2030s
August 12, 2022
-
REGULATORY Chuikyo OKs Lagevrio, Voxzogo, Enjaymo, and More for August Listing, BioMarin Med with Biggest Peak Sales Outlook
August 10, 2022
-
REGULATORY Rybelsus Faces 2.5-2.6% Price Cut in November under CEA Scheme; No Change for Cabometyx
August 10, 2022
-
BUSINESS Sumitomo Drops 100 Billion Yen Diabetes Sales Goal as Trulicity Collab Ends
August 10, 2022
-
BUSINESS Yen’s Fall Reaps 10 Billion Yen-Plus Gain on Sales for 5 Japan Makers, Takeda Gets 8.8 Billion Yen: April-June
August 9, 2022
-
BUSINESS Pfizer Seeks Japan Nod for Omicron-Adapted Bivalent Jab
August 9, 2022
-
BUSINESS Single-Wholesaler Distribution Unlikely to Constitute Antimonopoly Law Violation: Expert
August 8, 2022
-
REGULATORY LDP Project Team to Make Proposals for Japan-Moderna Deal
August 8, 2022
-
BUSINESS Moderna Eyes mRNA Plant in Japan, but Multi-Year Purchase Pact a Must: Local President
August 5, 2022
-
ORGANIZATION Single-Wholesaler Distribution Should Be Redressed from Stable Supply Standpoint: JMA Official
August 4, 2022
-
BUSINESS Trulicity Sales Alliance Deal to Expire by 2022-End: Lilly Japan/Sumitomo
August 4, 2022
-
BUSINESS Mitsubishi to Review Biz Plan around Medicago’s COVID Jab, Reexamine Japan Timeline Too
August 4, 2022
-
REGULATORY Chuikyo Will Consider Any Proposals of New Panel on Drug Pricing: Pharma Management Director
August 3, 2022
-
REGULATORY Japan Approves KM Biologics’ Smallpox Vaccine for Monkeypox
August 2, 2022
-
BUSINESS Shionogi Eyes PIII Topline Readout for COVID Pill in Aug-Sept., Sticks to H1 Approval Plan
August 2, 2022
-
REGULATORY KM Biologics’s Smallpox Vaccine in Line to Add Monkeypox Use
August 1, 2022
-
REGULATORY New Expert Panel to Issue Proposals for 2023, 2024 Price Revisions; Official Spearheading Debate Prods Industry to Speak Up
July 29, 2022
-
BUSINESS Takeda to Lift Restricted Shipments for Leuplin in September after Over 2 Years
July 29, 2022
-
BUSINESS Mochida to Quit Filgrastim Biosimilar as Repeated Price Cuts Made It Unprofitable
July 28, 2022
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…